{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:27:14Z","timestamp":1780774034713,"version":"3.54.1"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001108","name":"Ophthalmic Research Institute of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05636-4","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T07:33:31Z","timestamp":1766993611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Selective Receptor Modulation by Truncated Neuropeptide Y (3\u201336) Dissociates Vasoconstriction from Neuroprotection in Experimental Glaucoma"],"prefix":"10.1007","volume":"63","author":[{"given":"Viswanthram","family":"Palanivel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devaraj","family":"Basavarajappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akanksha","family":"Salkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s M.","family":"Kom\u00e1romy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Tietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taslima Akter","family":"Eva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Chitranshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veer","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyi","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart L.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"3","key":"5636_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0163-7258(95)98598-K","volume":"65","author":"JG Wettstein","year":"1995","unstructured":"Wettstein JG, Earley B, Junien JL (1995) Central nervous system pharmacology of neuropeptide Y. Pharmacol Ther 65(3):397\u2013414","journal-title":"Pharmacol Ther"},{"issue":"6","key":"5636_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.npep.2012.09.001","volume":"46","author":"JO Malva","year":"2012","unstructured":"Malva JO et al (2012) Multifaces of neuropeptide Y in the brain\u2013neuroprotection, neurogenesis and neuroinflammation. Neuropeptides 46(6):299\u2013308","journal-title":"Neuropeptides"},{"key":"5636_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2013.00005","volume":"4","author":"X Pedragosa-Badia","year":"2013","unstructured":"Pedragosa-Badia X, Stichel J, Beck-Sickinger AG (2013) Neuropeptide Y receptors: how to get subtype selectivity. Front Endocrinol (Lausanne) 4:5","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"5636_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/(SICI)1099-1387(200003)6:3<97::AID-PSC236>3.0.CO;2-E","volume":"6","author":"C Cabrele","year":"2000","unstructured":"Cabrele C, Beck-Sickinger AG (2000) Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. J Pept Sci 6(3):97\u2013122","journal-title":"J Pept Sci"},{"issue":"18","key":"5636_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm1232","volume":"8","author":"T Tang","year":"2022","unstructured":"Tang T et al (2022) Receptor-specific recognition of NPY peptides revealed by structures of NPY receptors. Sci Adv 8(18):eabm1232","journal-title":"Sci Adv"},{"key":"5636_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.nbd.2016.07.022","volume":"95","author":"J Duarte-Neves","year":"2016","unstructured":"Duarte-Neves J, de Pereira Almeida L, Cavadas C (2016) Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases. Neurobiol Dis 95:210\u2013224","journal-title":"Neurobiol Dis"},{"issue":"9","key":"5636_CR7","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.2174\/1570159X19666210906120302","volume":"20","author":"S Pain","year":"2022","unstructured":"Pain S, Brot S, Gaillard A (2022) Neuroprotective effects of neuropeptide Y against neurodegenerative disease. Curr Neuropharmacol 20(9):1717\u20131725","journal-title":"Curr Neuropharmacol"},{"key":"5636_CR8","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3389\/fnins.2019.00869","volume":"13","author":"C Li","year":"2019","unstructured":"Li C et al (2019) Roles of neuropeptide Y in neurodegenerative and neuroimmune diseases. Front Neurosci 13:869","journal-title":"Front Neurosci"},{"key":"5636_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.pneurobio.2013.10.002","volume":"112","author":"A Santos-Carvalho","year":"2014","unstructured":"Santos-Carvalho A et al (2014) Emerging novel roles of neuropeptide Y in the retina: from neuromodulation to neuroprotection. Prog Neurobiol 112:70\u201379","journal-title":"Prog Neurobiol"},{"issue":"6","key":"5636_CR10","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.3390\/neurolint16060100","volume":"16","author":"K Shapovalova","year":"2024","unstructured":"Shapovalova K et al (2024) The role of neuropeptide Y in the pathogenesis of Alzheimer\u2019s disease: diagnostic significance and neuroprotective functions. Neurol Int 16(6):1318\u20131331","journal-title":"Neurol Int"},{"issue":"2","key":"5636_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0022-3565(25)22241-8","volume":"250","author":"JP Hieble","year":"1989","unstructured":"Hieble JP, Jr Duesler JG, Daly RN (1989) Effects of neuropeptide Y on the response of isolated blood vessels to norepinephrine and sympathetic field stimulation. J Pharmacol Exp Ther 250(2):523\u2013528","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"5636_CR12","first-page":"H290","volume":"274","author":"S Han","year":"1998","unstructured":"Han S et al (1998) Direct evidence for the role of neuropeptide Y in sympathetic nerve stimulation-induced vasoconstriction. Am J Physiol 274(1):H290\u2013H294","journal-title":"Am J Physiol"},{"issue":"6","key":"5636_CR13","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1073\/pnas.96.6.3239","volume":"96","author":"AS Leonard","year":"1999","unstructured":"Leonard AS et al (1999) Calcium\/calmodulin-dependent protein kinase II is associated with the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 96(6):3239\u20133244","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5636_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.yjmcc.2004.11.001","volume":"38","author":"P Heredia Mdel","year":"2005","unstructured":"Heredia Mdel P et al (2005) Neuropeptide Y rapidly enhances [Ca2+]i transients and Ca2+ sparks in adult rat ventricular myocytes through Y1 receptor and PLC activation. J Mol Cell Cardiol 38(1):205\u2013212","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"5636_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0014-5793(90)80069-U","volume":"260","author":"L Aakerlund","year":"1990","unstructured":"Aakerlund L et al (1990) Y1 receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase. FEBS Lett 260(1):73\u201378","journal-title":"FEBS Lett"},{"issue":"2","key":"5636_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/bip.360370207","volume":"37","author":"AG Beck-Sickinger","year":"1995","unstructured":"Beck-Sickinger AG, Jung G (1995) Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors. Biopolymers 37(2):123\u2013142","journal-title":"Biopolymers"},{"issue":"1","key":"5636_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0167-0115(96)00073-0","volume":"65","author":"S Hoffmann","year":"1996","unstructured":"Hoffmann S et al (1996) Structure-affinity studies of C-terminally modified analogs of neuropeptide Y led to a novel class of peptidic Y1 receptor antagonist. Regul Pept 65(1):61\u201370","journal-title":"Regul Pept"},{"issue":"3","key":"5636_CR18","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1161\/HYPERTENSIONAHA.118.11498","volume":"72","author":"SA Hubers","year":"2018","unstructured":"Hubers SA et al (2018) DPP (dipeptidyl peptidase)-4 inhibition potentiates the vasoconstrictor response to NPY (neuropeptide Y) in humans during renin-angiotensin-aldosterone system inhibition. Hypertension 72(3):712\u2013719","journal-title":"Hypertension"},{"issue":"8","key":"5636_CR19","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/aos.13806","volume":"96","author":"AT Christiansen","year":"2018","unstructured":"Christiansen AT et al (2018) Neuropeptide Y treatment induces retinal vasoconstriction and causes functional and histological retinal damage in a porcine ischaemia model. Acta Ophthalmol 96(8):812\u2013820","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"5636_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.preteyeres.2011.11.002","volume":"31","author":"M Almasieh","year":"2012","unstructured":"Almasieh M et al (2012) The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res 31(2):152\u2013181","journal-title":"Prog Retin Eye Res"},{"key":"5636_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2019.07.002","volume":"73","author":"SB Syc-Mazurek","year":"2019","unstructured":"Syc-Mazurek SB, Libby RT (2019) Axon injury signaling and compartmentalized injury response in glaucoma. Prog Retin Eye Res 73:100769","journal-title":"Prog Retin Eye Res"},{"key":"5636_CR22","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028035","author":"BN Dugger","year":"2017","unstructured":"Dugger BN, Dickson DW (2017) Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol. https:\/\/doi.org\/10.1101\/cshperspect.a028035","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"5636_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/OPX.0b013e31817841e5","volume":"85","author":"W Cheung","year":"2008","unstructured":"Cheung W, Guo L, Cordeiro MF (2008) Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci 85(6):406\u2013416","journal-title":"Optom Vis Sci"},{"issue":"1","key":"5636_CR24","first-page":"143","volume":"11","author":"HL Zeng","year":"2018","unstructured":"Zeng HL, Shi JM (2018) The role of microglia in the progression of glaucomatous neurodegeneration- a review. Int J Ophthalmol 11(1):143\u2013149","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"5636_CR25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jphs.2020.12.009","volume":"145","author":"Y Shinozaki","year":"2021","unstructured":"Shinozaki Y, Koizumi S (2021) Potential roles of astrocytes and muller cells in the pathogenesis of glaucoma. J Pharmacol Sci 145(3):262\u2013267","journal-title":"J Pharmacol Sci"},{"issue":"5","key":"5636_CR26","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1111\/j.1471-4159.2009.06079.x","volume":"109","author":"AR Alvaro","year":"2009","unstructured":"Alvaro AR et al (2009) Neuropeptide Y inhibits [Ca2+]i changes in rat retinal neurons through NPY Y1, Y4, and Y5 receptors. J Neurochem 109(5):1508\u20131515","journal-title":"J Neurochem"},{"issue":"3","key":"5636_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/cne.10184","volume":"446","author":"SJ Oh","year":"2002","unstructured":"Oh SJ et al (2002) Distribution and synaptic connectivity of neuropeptide Y-immunoreactive amacrine cells in the rat retina. J Comp Neurol 446(3):219\u2013234","journal-title":"J Comp Neurol"},{"issue":"5","key":"5636_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.160","volume":"4","author":"A Santos-Carvalho","year":"2013","unstructured":"Santos-Carvalho A et al (2013) Neuropeptide Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate. Cell Death Dis 4(5):e636","journal-title":"Cell Death Dis"},{"key":"5636_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/1759091415598292","author":"J Martins","year":"2015","unstructured":"Martins J et al (2015) Activation of neuropeptide Y receptors modulates retinal ganglion cell physiology and exerts neuroprotective actions in vitro. ASN Neuro. https:\/\/doi.org\/10.1177\/1759091415598292","journal-title":"ASN Neuro"},{"key":"5636_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/aos.16228","author":"V Palanivel","year":"2024","unstructured":"Palanivel V et al (2024) Protective effects of neuropeptide Y treatment on retina in a mouse model of experimental glaucoma. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/aos.16228","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"5636_CR31","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.ophtha.2013.10.022","volume":"121","author":"M Sehi","year":"2014","unstructured":"Sehi M et al (2014) Retinal blood flow in glaucomatous eyes with single-hemifield damage. Ophthalmology 121(3):750\u2013758","journal-title":"Ophthalmology"},{"issue":"1","key":"5636_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2016-000032","volume":"1","author":"KKW Chan","year":"2017","unstructured":"Chan KKW et al (2017) Retinal vasculature in glaucoma: a review. BMJ Open Ophthalmol 1(1):e000032","journal-title":"BMJ Open Ophthalmol"},{"issue":"8","key":"5636_CR33","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/j.1460-9568.2008.06172.x","volume":"27","author":"S Xapelli","year":"2008","unstructured":"Xapelli S et al (2008) Interaction between neuropeptide Y (NPY) and brain-derived neurotrophic factor in NPY-mediated neuroprotection against excitotoxicity: a role for microglia. Eur J Neurosci 27(8):2089\u20132102","journal-title":"Eur J Neurosci"},{"issue":"8","key":"5636_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgae299","volume":"3","author":"V Palanivel","year":"2024","unstructured":"Palanivel V et al (2024) Neuropeptide Y receptor activation preserves inner retinal integrity through PI3K\/Akt signaling in a glaucoma mouse model. PNAS Nexus 3(8):pgae299","journal-title":"PNAS Nexus"},{"issue":"12","key":"5636_CR35","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.1007\/s12035-023-03535-0","volume":"60","author":"D Basavarajappa","year":"2023","unstructured":"Basavarajappa D et al (2023) Anti-inflammatory effects of Siponimod in a mouse model of excitotoxicity-induced retinal injury. Mol Neurobiol 60(12):7222\u20137237","journal-title":"Mol Neurobiol"},{"issue":"5","key":"5636_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197048","volume":"13","author":"RL Rausch","year":"2018","unstructured":"Rausch RL, Libby RT, Kiernan AE (2018) Ciliary margin-derived BMP4 does not have a major role in ocular development. PLoS One 13(5):e0197048","journal-title":"PLoS One"},{"issue":"9","key":"5636_CR37","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41419-020-02990-0","volume":"11","author":"OJ Marola","year":"2020","unstructured":"Marola OJ et al (2020) Endothelin 1-induced retinal ganglion cell death is largely mediated by JUN activation. Cell Death Dis 11(9):811","journal-title":"Cell Death Dis"},{"key":"5636_CR38","doi-asserted-by":"crossref","unstructured":"Adini I, Ghosh K (2015) Mouse retinal whole mounts and quantification of vasculature protocol. Bio Protoc 5(15)","DOI":"10.21769\/BioProtoc.1546"},{"issue":"1","key":"5636_CR39","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41598-020-80308-y","volume":"11","author":"L Masin","year":"2021","unstructured":"Masin L et al (2021) A novel retinal ganglion cell quantification tool based on deep learning. Sci Rep 11(1):702","journal-title":"Sci Rep"},{"issue":"4","key":"5636_CR40","doi-asserted-by":"publisher","first-page":"840","DOI":"10.4103\/1673-5374.344952","volume":"18","author":"D Basavarajappa","year":"2023","unstructured":"Basavarajappa D et al (2023) Siponimod exerts neuroprotective effects on the retina and higher visual pathway through neuronal S1PR1 in experimental glaucoma. Neural Regen Res 18(4):840\u2013848","journal-title":"Neural Regen Res"},{"issue":"7","key":"5636_CR41","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1016\/j.ymthe.2023.03.008","volume":"31","author":"N Chitranshi","year":"2023","unstructured":"Chitranshi N et al (2023) Neuroserpin gene therapy inhibits retinal ganglion cell apoptosis and promotes functional preservation in glaucoma. Mol Ther 31(7):2056\u20132076","journal-title":"Mol Ther"},{"key":"5636_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neuroscience.2022.01.020","volume":"490","author":"V Gupta","year":"2022","unstructured":"Gupta V et al (2022) TrkB receptor agonist 7,8 dihydroxyflavone is protective against the inner retinal deficits induced by experimental glaucoma. Neuroscience 490:36\u201348","journal-title":"Neuroscience"},{"issue":"6","key":"5636_CR43","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202402642R","volume":"39","author":"D Basavarajappa","year":"2025","unstructured":"Basavarajappa D et al (2025) Retinoid X receptor agonist 9CDHRA mitigates retinal ganglion cell apoptosis and neuroinflammation in a mouse model of glaucoma. FASEB J 39(6):e70465","journal-title":"FASEB J"},{"issue":"1","key":"5636_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40478-024-01804-0","volume":"12","author":"KPM Thananthirige","year":"2024","unstructured":"Thananthirige KPM et al (2024) Tau modulation through AAV9 therapy augments Akt\/Erk survival signalling in glaucoma mitigating the retinal degenerative phenotype. Acta Neuropathol Commun 12(1):89","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"5636_CR45","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202201346R","volume":"37","author":"D Basavarajappa","year":"2023","unstructured":"Basavarajappa D et al (2023) S1pr1 signaling attenuates apoptosis of retinal ganglion cells via modulation of cJun\/Bim cascade and Bad phosphorylation in a mouse model of glaucoma. FASEB J 37(1):e22710","journal-title":"FASEB J"},{"issue":"9","key":"5636_CR46","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.bbadis.2014.05.026","volume":"1842","author":"V Gupta","year":"2014","unstructured":"Gupta V et al (2014) BDNF impairment is associated with age-related changes in the inner retina and exacerbates experimental glaucoma. Biochim Biophys Acta 1842(9):1567\u20131578","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"5636_CR47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1167\/iovs.65.13.50","volume":"65","author":"R Vander Wall","year":"2024","unstructured":"Vander Wall R et al (2024) VEP latency delay reflects demyelination beyond the optic nerve in the cuprizone model. Invest Ophthalmol Vis Sci 65(13):50","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5636_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.08.034","author":"N Chitranshi","year":"2025","unstructured":"Chitranshi N et al (2025) Retinoid X receptor alpha overexpression protects retinal ganglion cells and modulates inflammatory response in experimental glaucoma. Mol Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.034","journal-title":"Mol Ther"},{"issue":"8","key":"5636_CR49","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1167\/iovs.08-3267","volume":"50","author":"FM Nadal-Nicol\u00e1s","year":"2009","unstructured":"Nadal-Nicol\u00e1s FM et al (2009) Brn3a as a marker of retinal ganglion cells: qualitative and quantitative time course studies in naive and optic nerve-injured retinas. Invest Ophthalmol Vis Sci 50(8):3860\u20133868","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"5636_CR50","first-page":"208","volume":"61","author":"M Alayl\u0131o\u011flu","year":"2024","unstructured":"Alayl\u0131o\u011flu M et al (2024) A novel and robust protocol for differentiation of SH-SY5Y neuroblastoma cells into neuron like cells. Noro Psikiyatr Ars 61(3):208\u2013212","journal-title":"Noro Psikiyatr Ars"},{"issue":"12","key":"5636_CR51","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/IJG.0000000000001894","volume":"30","author":"AM Levin","year":"2021","unstructured":"Levin AM et al (2021) Intraocular pressure elevation following intravitreal anti-VEGF injections: short- and long-term considerations. J Glaucoma 30(12):1019\u20131026","journal-title":"J Glaucoma"},{"issue":"1","key":"5636_CR52","doi-asserted-by":"publisher","first-page":"13248","DOI":"10.1038\/s41598-020-70269-7","volume":"10","author":"VA de Vries","year":"2020","unstructured":"de Vries VA, Bassil FL, Ramdas WD (2020) The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci Rep 10(1):13248","journal-title":"Sci Rep"},{"issue":"23","key":"5636_CR53","doi-asserted-by":"publisher","first-page":"12661","DOI":"10.1073\/pnas.94.23.12661","volume":"94","author":"L Bao","year":"1997","unstructured":"Bao L et al (1997) Localization of neuropeptide Y Y1 receptors in cerebral blood vessels. Proc Natl Acad Sci U S A 94(23):12661\u201312666","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5636_CR54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pharmthera.2004.11.002","volume":"106","author":"ME Anderson","year":"2005","unstructured":"Anderson ME (2005) Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharmacol Ther 106(1):39\u201355","journal-title":"Pharmacol Ther"},{"issue":"1","key":"5636_CR55","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1167\/iovs.12-10581","volume":"54","author":"BJ Frankfort","year":"2013","unstructured":"Frankfort BJ et al (2013) Elevated intraocular pressure causes inner retinal dysfunction before cell loss in a mouse model of experimental glaucoma. Invest Ophthalmol Vis Sci 54(1):762\u2013770","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"5636_CR56","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1152\/physrev.00041.2013","volume":"94","author":"M Pekny","year":"2014","unstructured":"Pekny M, Pekna M (2014) Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiol Rev 94(4):1077\u20131098","journal-title":"Physiol Rev"},{"issue":"1","key":"5636_CR57","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s40478-025-02066-0","volume":"13","author":"A Salkar","year":"2025","unstructured":"Salkar A et al (2025) Glial and immune dysregulation in glaucoma independent of retinal ganglion cell loss: a human post-mortem histopathology study. Acta Neuropathol Commun 13(1):141","journal-title":"Acta Neuropathol Commun"},{"issue":"7","key":"5636_CR58","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1093\/brain\/awaa098","volume":"143","author":"AR Gafson","year":"2020","unstructured":"Gafson AR et al (2020) Neurofilaments: neurobiological foundations for biomarker applications. Brain 143(7):1975\u20131998","journal-title":"Brain"},{"issue":"1","key":"5636_CR59","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1167\/iovs.02-0398","volume":"44","author":"K Kashiwagi","year":"2003","unstructured":"Kashiwagi K et al (2003) Increase in dephosphorylation of the heavy neurofilament subunit in the monkey chronic glaucoma model. Invest Ophthalmol Vis Sci 44(1):154\u2013159","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"5636_CR60","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00401-011-0807-1","volume":"121","author":"G Chidlow","year":"2011","unstructured":"Chidlow G et al (2011) The optic nerve head is the site of axonal transport disruption, axonal cytoskeleton damage and putative axonal regeneration failure in a rat model of glaucoma. Acta Neuropathol 121(6):737\u2013751","journal-title":"Acta Neuropathol"},{"key":"5636_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cells11223665","author":"V Palanivel","year":"2022","unstructured":"Palanivel V et al (2022) Neuroprotective effects of neuropeptide Y on human neuroblastoma SH-SY5Y cells in glutamate excitotoxicity and ER stress conditions. Cells. https:\/\/doi.org\/10.3390\/cells11223665","journal-title":"Cells"},{"issue":"4","key":"5636_CR62","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1111\/aos.12298","volume":"92","author":"VP Costa","year":"2014","unstructured":"Costa VP et al (2014) Ocular perfusion pressure in glaucoma. Acta Ophthalmol 92(4):e252\u2013e266","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"5636_CR63","doi-asserted-by":"publisher","first-page":"10056","DOI":"10.1038\/s41598-020-66914-w","volume":"10","author":"KE Kim","year":"2020","unstructured":"Kim KE et al (2020) Ocular perfusion pressure and the risk of open-angle glaucoma: systematic review and meta-analysis. Sci Rep 10(1):10056","journal-title":"Sci Rep"},{"key":"5636_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2022.101095","volume":"91","author":"H Hanssen","year":"2022","unstructured":"Hanssen H, Streese L, Vilser W (2022) Retinal vessel diameters and function in cardiovascular risk and disease. Prog Retin Eye Res 91:101095","journal-title":"Prog Retin Eye Res"},{"key":"5636_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2020.106810","volume":"136","author":"MDC Gonzalez-Montelongo","year":"2021","unstructured":"Gonzalez-Montelongo MDC, Fountain SJ (2021) Neuropeptide Y facilitates P2X1 receptor-dependent vasoconstriction via Y1 receptor activation in small mesenteric arteries during sympathetic neurogenic responses. Vascul Pharmacol 136:106810","journal-title":"Vascul Pharmacol"},{"issue":"2","key":"5636_CR66","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s000180300029","volume":"60","author":"T Pedrazzini","year":"2003","unstructured":"Pedrazzini T, Pralong F, Grouzmann E (2003) Neuropeptide Y: the universal soldier. Cell Mol Life Sci 60(2):350\u2013377","journal-title":"Cell Mol Life Sci"},{"issue":"17","key":"5636_CR67","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.2174\/156802607782340948","volume":"7","author":"K Abe","year":"2007","unstructured":"Abe K, Tilan JU, Zukowska Z (2007) NPY and NPY receptors in vascular remodeling. Curr Top Med Chem 7(17):1704\u20131709","journal-title":"Curr Top Med Chem"},{"issue":"22","key":"5636_CR68","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1021\/bi800181k","volume":"47","author":"D Lindner","year":"2008","unstructured":"Lindner D et al (2008) GPC receptors and not ligands decide the binding mode in neuropeptide Y multireceptor\/multiligand system. Biochemistry 47(22):5905\u20135914","journal-title":"Biochemistry"},{"issue":"3","key":"5636_CR69","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1021\/jm00055a010","volume":"36","author":"DA Kirby","year":"1993","unstructured":"Kirby DA et al (1993) Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues. J Med Chem 36(3):385\u2013393","journal-title":"J Med Chem"},{"issue":"7702","key":"5636_CR70","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41586-018-0046-x","volume":"556","author":"Z Yang","year":"2018","unstructured":"Yang Z et al (2018) Structural basis of ligand binding modes at the neuropeptide Y Y(1) receptor. Nature 556(7702):520\u2013524","journal-title":"Nature"},{"issue":"3","key":"5636_CR71","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.1432-1033.1994.0947b.x","volume":"225","author":"AG Beck-Sickinger","year":"1994","unstructured":"Beck-Sickinger AG et al (1994) Complete l-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations. Eur J Biochem 225(3):947\u2013958","journal-title":"Eur J Biochem"},{"issue":"1","key":"5636_CR72","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.peptides.2012.06.014","volume":"37","author":"J Rosmaninho-Salgado","year":"2012","unstructured":"Rosmaninho-Salgado J et al (2012) Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-gamma expression. Peptides 37(1):49\u201354","journal-title":"Peptides"},{"issue":"12","key":"5636_CR73","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.bbadis.2010.01.005","volume":"1802","author":"HL Brinks","year":"2010","unstructured":"Brinks HL, Eckhart AD (2010) Regulation of GPCR signaling in hypertension. Biochim Biophys Acta 1802(12):1268\u20131275","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"5636_CR74","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0196-9781(01)00583-6","volume":"23","author":"S Sheriff","year":"2002","unstructured":"Sheriff S et al (2002) Predominant role by CaM kinase in NPY Y(1) receptor signaling: involvement of CREB [corrected]. Peptides 23(1):87\u201396","journal-title":"Peptides"},{"issue":"5","key":"5636_CR75","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/MAJ.0000000000000319","volume":"348","author":"CX Hu","year":"2014","unstructured":"Hu CX et al (2014) What do patients with glaucoma see? Visual symptoms reported by patients with glaucoma. Am J Med Sci 348(5):403\u2013409","journal-title":"Am J Med Sci"},{"key":"5636_CR76","doi-asserted-by":"publisher","first-page":"1091697","DOI":"10.3389\/fneur.2023.1091697","volume":"14","author":"L Zhou","year":"2023","unstructured":"Zhou L et al (2023) Alteration of neurofilament heavy chain and its phosphoforms reveals early subcellular damage beyond the optic nerve head in glaucoma. Front Neurol 14:1091697","journal-title":"Front Neurol"},{"issue":"2","key":"5636_CR77","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.neuron.2013.12.034","volume":"81","author":"JE Burda","year":"2014","unstructured":"Burda JE, Sofroniew MV (2014) Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 81(2):229\u2013248","journal-title":"Neuron"},{"key":"5636_CR78","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1742-2094-8-169","volume":"8","author":"R Ferreira","year":"2011","unstructured":"Ferreira R et al (2011) Neuropeptide Y inhibits interleukin-1beta-induced phagocytosis by microglial cells. J Neuroinflammation 8:169","journal-title":"J Neuroinflammation"},{"issue":"1","key":"5636_CR79","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1471-4159.2011.07541.x","volume":"120","author":"R Ferreira","year":"2012","unstructured":"Ferreira R et al (2012) Neuropeptide Y inhibits interleukin-1 beta-induced microglia motility. J Neurochem 120(1):93\u2013105","journal-title":"J Neurochem"},{"issue":"1\u20132","key":"5636_CR80","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0006-8993(01)02141-2","volume":"896","author":"A Barnea","year":"2001","unstructured":"Barnea A et al (2001) Interleukin-1beta induces expression of neuropeptide Y in primary astrocyte cultures in a cytokine-specific manner: induction in human but not rat astrocytes. Brain Res 896(1\u20132):137\u2013145","journal-title":"Brain Res"},{"issue":"5","key":"5636_CR81","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ejcb.2018.04.003","volume":"97","author":"DY Lee","year":"2018","unstructured":"Lee DY et al (2018) Neuropeptide Y mitigates ER stress-induced neuronal cell death by activating the PI3K-XBP1 pathway. Eur J Cell Biol 97(5):339\u2013348","journal-title":"Eur J Cell Biol"},{"issue":"3","key":"5636_CR82","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.npep.2009.02.002","volume":"43","author":"M Smialowska","year":"2009","unstructured":"Smialowska M et al (2009) Neuroprotective effects of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo. Neuropeptides 43(3):235\u2013249","journal-title":"Neuropeptides"},{"issue":"9","key":"5636_CR83","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1096\/fj.02-0885fje","volume":"17","author":"AP Silva","year":"2003","unstructured":"Silva AP et al (2003) Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. FASEB J 17(9):1118\u20131120","journal-title":"FASEB J"},{"issue":"6","key":"5636_CR84","doi-asserted-by":"publisher","first-page":"7872","DOI":"10.18632\/aging.202805","volume":"13","author":"M Ferreira-Marques","year":"2021","unstructured":"Ferreira-Marques M et al (2021) PI3K\/AKT\/MTOR and ERK1\/2-MAPK signaling pathways are involved in autophagy stimulation induced by caloric restriction or caloric restriction mimetics in cortical neurons. Aging Albany NY 13(6):7872\u20137882","journal-title":"Aging Albany NY"},{"key":"5636_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020446","author":"D Sousa","year":"2023","unstructured":"Sousa D et al (2023) The bidirectional relationship of NPY and mitochondria in energy balance regulation. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11020446","journal-title":"Biomedicines"},{"issue":"5","key":"5636_CR86","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.neuint.2007.01.010","volume":"50","author":"AR Alvaro","year":"2007","unstructured":"Alvaro AR et al (2007) NPY in rat retina is present in neurons, in endothelial cells and also in microglial and M\u00fcller cells. Neurochem Int 50(5):757\u2013763","journal-title":"Neurochem Int"},{"issue":"53","key":"5636_CR87","doi-asserted-by":"publisher","first-page":"41921","DOI":"10.1074\/jbc.M110.164020","volume":"285","author":"R Ferreira","year":"2010","unstructured":"Ferreira R et al (2010) Neuropeptide Y modulation of interleukin-1beta (IL-1beta)-induced nitric oxide production in microglia. J Biol Chem 285(53):41921\u201341934","journal-title":"J Biol Chem"},{"issue":"9","key":"5636_CR88","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1111\/j.1460-9568.2012.08232.x","volume":"36","author":"J Goncalves","year":"2012","unstructured":"Goncalves J et al (2012) Protective role of neuropeptide Y Y(2) receptors in cell death and microglial response following methamphetamine injury. Eur J Neurosci 36(9):3173\u20133183","journal-title":"Eur J Neurosci"},{"issue":"11","key":"5636_CR89","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/0028-3908(95)00068-H","volume":"34","author":"R McDonald","year":"1995","unstructured":"McDonald R et al (1995) Inhibition of Ca2+ channel currents in human neuroblastoma (SH-SY5Y) cells by neuropeptide Y and a novel cyclic neuropeptide Y analogue. Neuropharmacology 34(11):1507\u20131514","journal-title":"Neuropharmacology"},{"issue":"3","key":"5636_CR90","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/sj.bjp.0700920","volume":"120","author":"M Connor","year":"1997","unstructured":"Connor M, Yeo A, Henderson G (1997) Neuropeptide Y Y2 receptor and somatostatin sst2 receptor coupling to mobilization of intracellular calcium in SH-SY5Y human neuroblastoma cells. Br J Pharmacol 120(3):455\u2013463","journal-title":"Br J Pharmacol"},{"issue":"1","key":"5636_CR91","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2191-219X-1-21","volume":"1","author":"D Chatenet","year":"2011","unstructured":"Chatenet D et al (2011) Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers. EJNMMI Res 1(1):21","journal-title":"EJNMMI Res"},{"issue":"4","key":"5636_CR92","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1081\/RRS-120026974","volume":"23","author":"MM H\u00f6fliger","year":"2003","unstructured":"H\u00f6fliger MM et al (2003) Novel cell line selectively expressing neuropeptide Y-Y2 receptors. J Recept Signal Transduct Res 23(4):351\u2013360","journal-title":"J Recept Signal Transduct Res"},{"issue":"53","key":"5636_CR93","doi-asserted-by":"publisher","first-page":"41578","DOI":"10.1074\/jbc.M110.162156","volume":"285","author":"C Walther","year":"2010","unstructured":"Walther C et al (2010) Ligand-induced internalization and recycling of the human neuropeptide Y2 receptor is regulated by its carboxyl-terminal tail. J Biol Chem 285(53):41578\u201341590","journal-title":"J Biol Chem"},{"issue":"1","key":"5636_CR94","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0014-2999(03)02039-9","volume":"474","author":"SL Parker","year":"2003","unstructured":"Parker SL et al (2003) Ligand internalization by cloned neuropeptide Y Y5 receptors excludes Y2 and Y4 receptor-selective peptides. Eur J Pharmacol 474(1):31\u201342","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"5636_CR95","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1074\/jbc.M107224200","volume":"277","author":"H Gicquiaux","year":"2002","unstructured":"Gicquiaux H et al (2002) Rapid internalization and recycling of the human neuropeptide Y Y(1) receptor. J Biol Chem 277(8):6645\u20136655","journal-title":"J Biol Chem"},{"issue":"4","key":"5636_CR96","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/sj.bjp.0705306","volume":"139","author":"LH Pheng","year":"2003","unstructured":"Pheng LH et al (2003) Agonist- and antagonist-induced sequestration\/internalization of neuropeptide Y Y1 receptors in HEK293 cells. Br J Pharmacol 139(4):695\u2013704","journal-title":"Br J Pharmacol"},{"key":"5636_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01281","volume":"9","author":"CMJ Tan","year":"2018","unstructured":"Tan CMJ et al (2018) The role of neuropeptide Y in cardiovascular health and disease. Front Physiol 9:1281","journal-title":"Front Physiol"},{"issue":"7","key":"5636_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.565","volume":"5","author":"S Shen","year":"2024","unstructured":"Shen S et al (2024) Structural basis of neuropeptide Y signaling through Y(1) and Y(2) receptors. MedComm 5(7):e565","journal-title":"MedComm"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05636-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05636-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05636-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T09:01:35Z","timestamp":1766998895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05636-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5636"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05636-4","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors utilised ChatGPT to rephrase certain sections of the manuscript to enhance readability and clarity. After using this tool\/service, the author reviewed and edited the content as needed and took full responsibility for the content of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of Generative AI"}},{"value":"Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Viswanthram Palanivel (viswa.palanivel@mq.edu.au).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Lead Contact"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"334"}}